P glycoprotein (P-gp) and drug resistance – time for reappraisal?
Open Access
- 1 April 1993
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 67 (4) , 641-643
- https://doi.org/10.1038/bjc.1993.119
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsPublished by Elsevier ,2003
- Clinical Correlates of MDR1 (P-glycoprotein) Gene Expression in Ovarian and Small-Cell Lung CarcinomasJNCI Journal of the National Cancer Institute, 1992
- Modulation of multidrug-resistant multiple myeloma by cyclosporinThe Lancet, 1992
- P-Glycoprotein Expression as a Predictor of the Outcome of Therapy for NeuroblastomaNew England Journal of Medicine, 1991
- Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cellsCell, 1991
- Clinical Relevance of Immunohistochemical Detection of Multidrug Resistance P-Glycoprotein in Breast CarcinomaJNCI Journal of the National Cancer Institute, 1991
- Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.Journal of Histochemistry & Cytochemistry, 1990
- Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin ABiochemical Pharmacology, 1989
- Multidrug Resistance: Molecular Biology Clinical RelevanceJNCI Journal of the National Cancer Institute, 1989
- The effect of verapamil on the pharmacokinetics of adriamycinCancer Chemotherapy and Pharmacology, 1986